A phase 2 trial of neoadjuvant PD-1 vaccine IMU-201 (PD1-Vaxx) in operable dMMR/MSI-H Colorectal Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Sep 2024 New trial record
06 Sep 2024 According to an Imugene Limited medaia release, approximately 10 sites, 6 in Australia and 4 in the UK with approximately 44 patients to be enrolled in the study over about 18 months.
06 Sep 2024 According to an Imugene Limited medaia release, Dr Tony Dhillon based at the Royal Surrey Hospital NHS Foundation Trust in Surrey is the Chief Investigator and Prof.Timothy Price from the Queen Elizabeth Hospital in Adelaide, is the Co-Chief Investigator of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com